Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

First phase II results for Innapharma's peptide antidepressant

Dec. 30, 1996

New agents for CNS disorders claimed by HHS

Dec. 30, 1996

Copaxone approved by FDA

Dec. 24, 1996

AACTG begins phase II memantine trial

Dec. 24, 1996

T Cell Sciences reports progress on TCAR program

Dec. 24, 1996

Otsuka describes new analgesics

Dec. 24, 1996

Neuroprotective polypeptide reported by Amgen

Dec. 24, 1996

Algos and Interneuron codevelop novel antimigraine combination

Dec. 23, 1996

Northwest Neurologic and Wyeth-Ayerst neurodegenerative disorder collaboration

Dec. 23, 1996

Regeneron claims novel use for neurotrophic factor

Dec. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...